Impact on antimicrobial consumption of procalcitonin-guided antibiotic therapy for pneumonia/pneumonitis associated with aspiration in comatose mechanically ventilated patients: a multicenter, randomized controlled study.
Aspiration
Coma
Intensive care unit
Pneumonia
Procalcitonin
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
12 Oct 2021
12 Oct 2021
Historique:
received:
27
06
2021
accepted:
21
09
2021
entrez:
12
10
2021
pubmed:
13
10
2021
medline:
13
10
2021
Statut:
epublish
Résumé
In comatose patients receiving oro-tracheal intubation for mechanical ventilation (MV), the risk of aspiration is increased. Aspiration can lead to chemical pneumonitis (inflammatory reaction to the gastric contents), or aspiration pneumonia (infection caused by inhalation of microorganisms). Distinguishing between the two types is challenging. We tested the interest of using a decisional algorithm based on procalcitonin (PCT) values to guide initiation and discontinuation of antibiotic therapies in intubated patients. The PROPASPI (PROcalcitonin Pneumonia/pneumonitis Associated with ASPIration) trial is a multicenter, prospective, randomized, controlled, single-blind, superiority study comparing two strategies: (1) an intervention group where threshold PCT values were used to guide initiation and discontinuation of antibiotics (PCT group); and (2) a control group, where antibiotic therapy was managed at the physician's discretion. Patients aged 18 years or over, intubated for coma (Glasgow score ≤ 8), with MV initiated within 48 h after admission, were eligible. The primary endpoint was the duration of antibiotic treatment during the first 15 days after admission to the ICU. From 24/2/2015 to 28/8/2019, 1712 patients were intubated for coma in the 5 participating centers, of whom 166 were included in the study. Data from 159 were available for intention-to-treat analysis: 81 in the PCT group, and 78 in the control group. Overall, 67 patients (43%) received antibiotics in the intensive care unit (ICU); there was no significant difference between groups (37 (46%) vs 30 (40%) for PCT vs control, p = 0.432). The mean duration of antibiotic treatment during the first 15 days in the ICU was 2.7 ± 3.8 days; there was no significant difference between groups (3.0 ± 4.1 days vs 2.3 ± 3.4 days for PCT vs control, p = 0.311). The mean number of days under MV was significantly higher in the PCT group (3.7 ± 3.6 days) than in controls (2.7 ± 2.5 days, p = 0.033). The duration of ICU stay was also significantly longer in the PCT group: 6.4 ± 6.5 days vs 4.6 ± 3.5 days in the control group (p = 0.043). After adjustment for SAPS II score, the difference in length of stay and duration of mechanical ventilation between groups was no longer significant. The use of PCT values to guide therapy, in comparison to the use of clinical, biological (apart from PCT) and radiological criteria, does not modify exposure to antibiotics in patients intubated for coma. Trial registration Clinicaltrials.gov Identifier NCT02862314.
Sections du résumé
BACKGROUND
BACKGROUND
In comatose patients receiving oro-tracheal intubation for mechanical ventilation (MV), the risk of aspiration is increased. Aspiration can lead to chemical pneumonitis (inflammatory reaction to the gastric contents), or aspiration pneumonia (infection caused by inhalation of microorganisms). Distinguishing between the two types is challenging. We tested the interest of using a decisional algorithm based on procalcitonin (PCT) values to guide initiation and discontinuation of antibiotic therapies in intubated patients.
METHODS
METHODS
The PROPASPI (PROcalcitonin Pneumonia/pneumonitis Associated with ASPIration) trial is a multicenter, prospective, randomized, controlled, single-blind, superiority study comparing two strategies: (1) an intervention group where threshold PCT values were used to guide initiation and discontinuation of antibiotics (PCT group); and (2) a control group, where antibiotic therapy was managed at the physician's discretion. Patients aged 18 years or over, intubated for coma (Glasgow score ≤ 8), with MV initiated within 48 h after admission, were eligible. The primary endpoint was the duration of antibiotic treatment during the first 15 days after admission to the ICU.
RESULTS
RESULTS
From 24/2/2015 to 28/8/2019, 1712 patients were intubated for coma in the 5 participating centers, of whom 166 were included in the study. Data from 159 were available for intention-to-treat analysis: 81 in the PCT group, and 78 in the control group. Overall, 67 patients (43%) received antibiotics in the intensive care unit (ICU); there was no significant difference between groups (37 (46%) vs 30 (40%) for PCT vs control, p = 0.432). The mean duration of antibiotic treatment during the first 15 days in the ICU was 2.7 ± 3.8 days; there was no significant difference between groups (3.0 ± 4.1 days vs 2.3 ± 3.4 days for PCT vs control, p = 0.311). The mean number of days under MV was significantly higher in the PCT group (3.7 ± 3.6 days) than in controls (2.7 ± 2.5 days, p = 0.033). The duration of ICU stay was also significantly longer in the PCT group: 6.4 ± 6.5 days vs 4.6 ± 3.5 days in the control group (p = 0.043). After adjustment for SAPS II score, the difference in length of stay and duration of mechanical ventilation between groups was no longer significant.
CONCLUSION
CONCLUSIONS
The use of PCT values to guide therapy, in comparison to the use of clinical, biological (apart from PCT) and radiological criteria, does not modify exposure to antibiotics in patients intubated for coma. Trial registration Clinicaltrials.gov Identifier NCT02862314.
Identifiants
pubmed: 34636974
doi: 10.1186/s13613-021-00931-4
pii: 10.1186/s13613-021-00931-4
pmc: PMC8505789
doi:
Banques de données
ClinicalTrials.gov
['NCT02862314']
Types de publication
Journal Article
Langues
eng
Pagination
145Subventions
Organisme : centre hospitalier universitaire de besançon
ID : APICHU 2016
Investigateurs
Jean-Christophe Navellou
(JC)
Claire Chaignat
(C)
Mathilde Grandperrin
(M)
Mélanie Claveau
(M)
Nicolas Belin
(N)
Cyrille Patry
(C)
Frédéric Claude
(F)
François Belon
(F)
Loïc Barrot
(L)
Marion Colnot
(M)
Guillaume Besch
(G)
Gilles Blasco
(G)
Marc Ginet
(M)
Yannick Brunin
(Y)
Pascal Andreu
(P)
Auguste Dargent
(A)
Pierre Emmanuel Charles
(PE)
Ferhat Meziani
(F)
Alexandra Monnier
(A)
Antoine Studer
(A)
Raphaël Clere-Jehl
(R)
Hassene Rahmani
(H)
Anne Florence Dureau
(AF)
Antoine Poidevin
(A)
Joy Mootien
(J)
Gokhan Bodur
(G)
Carmen Ionescu
(C)
Philippe Guiot
(P)
Informations de copyright
© 2021. The Author(s).
Références
Crit Care Med. 2001 Dec;29(12):2239-44
pubmed: 11801813
Chest. 2013 May;143(5):1219-1225
pubmed: 23715136
Am J Respir Crit Care Med. 1999 Jun;159(6):1742-6
pubmed: 10351912
Clin Infect Dis. 2020 Jan 1;70(1):11-18
pubmed: 30820545
Neurocrit Care. 2019 Apr;30(2):440-448
pubmed: 30267280
Anesthesiology. 2000 Sep;93(3):638-45
pubmed: 10969295
Ann Intensive Care. 2017 Dec;7(1):67
pubmed: 28620893
J Hosp Infect. 2019 Mar;101(3):272-275
pubmed: 30179656
Clin Infect Dis. 2004 Jul 15;39(2):206-17
pubmed: 15307030
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
Crit Care. 2009;13(3):R83
pubmed: 19493352
Resuscitation. 2013 Jun;84(6):776-81
pubmed: 23380286
Intensive Care Med. 2010 Jan;36(1):92-9
pubmed: 19844695
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Crit Care Med. 2009 Jan;37(1):159-66
pubmed: 19050600
Intensive Care Med. 2005 Apr;31(4):510-6
pubmed: 15754197
Ann Pharmacother. 2007 Apr;41(4):549-55
pubmed: 17389670
Lancet. 1996 Jul 13;348(9020):123-4
pubmed: 8676684
Am J Respir Crit Care Med. 1997 Dec;156(6):1922-9
pubmed: 9412576
Crit Care Med. 2011 Jun;39(6):1251-6
pubmed: 21283001
Crit Care Med. 2017 Aug;45(8):1268-1275
pubmed: 28594680
N Engl J Med. 2019 Feb 14;380(7):651-663
pubmed: 30763196
BMC Anesthesiol. 2015 Apr 29;15:65
pubmed: 25924678
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Lancet Infect Dis. 2016 Jul;16(7):819-827
pubmed: 26947523
N Engl J Med. 2001 Mar 1;344(9):665-71
pubmed: 11228282
Crit Care Med. 2011 Apr;39(4):818-26
pubmed: 21263315
BMJ Open. 2018 Oct 18;8(10):e021488
pubmed: 30341115
Curr Opin Infect Dis. 2019 Apr;32(2):152-157
pubmed: 30676341
Crit Care Med. 2013 Feb;41(2):580-637
pubmed: 23353941
Expert Rev Anti Infect Ther. 2021 Jun 4;:1-10
pubmed: 34027785
Lancet. 2010 Feb 6;375(9713):463-74
pubmed: 20097417
Am J Respir Crit Care Med. 1997 May;155(5):1729-34
pubmed: 9154884
BMC Infect Dis. 2014 Jan 09;14:13
pubmed: 24405683
J Crit Care. 2015 Feb;30(1):40-8
pubmed: 25129577
Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505
pubmed: 18096708
Wien Klin Wochenschr. 2001 Sep 17;113(17-18):676-80
pubmed: 11603102